Chemotherapy for non‐small cell lung cancer
93 results
1 - 93
Chemotherapy for non‐small cell lung cancer
Chemotherapy for advanced non-small cell lung cancer - Second‐line chemotherapy for non‐small cell lung cancer
- Chemotherapy for newly diagnosed advanced non-small-cell lung cancer
- Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer
- Chemotherapy for advanced non‐small cell lung cancer in the elderly population
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer: Cochrane systematic review
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer: Cochrane systematic review
- Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer: Cochrane systematic review
- Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
- Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease: Cochrane systematic review
- Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer
- Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
- Lung cancers
- Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer
- Platinum-based chemotherapy regimens for small-cell lung cancer
- Gefitinib for advanced non-small cell lung cancer: Cochrane systematic review
- Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
- Surgery for early stage non-small cell lung cancer
- Early versus late chest radiotherapy in patients with limited‐stage small cell lung cancer
- Surgery for local and locally advanced non‐small cell lung cancer
- Therapeutic vaccines for advanced non‐small cell lung cancer
- Chemotherapy versus best supportive care for extensive small cell lung cancer
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
- Palliative endobronchial brachytherapy for non‐small cell lung cancer
- Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
- Concurrent chemoradiotherapy in non‐small cell lung cancer
- Anti‐TIGIT inhibitors plus PD‐1 or PD‐L1 inhibitors versus PD‐1 or PD‐L1 inhibitors for first‐line treatment of advanced non‐small cell lung cancer
Patients with NSCLC treated with chemo before surgery live longer- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation
- Surgery for limited‐stage small‐cell lung cancer
- PET‐CT for assessing mediastinal lymph node involvement in patients with suspected resectable non‐small cell lung cancer
- Treatment of lung cancer
- First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
- Postoperative radiotherapy for non‐small cell lung cancer
- Chemotherapy versus best supportive care for extensive small cell lung cancer: Cochrane systematic review
- Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
- Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
- Erythropoietin or Darbepoetin for patients with cancer ‐ meta‐analysis based on individual patient data
- Cannabis‐based medicines and medical cannabis for adults with cancer pain
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer
- Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
- Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
- Chemotherapy for advanced gastric cancer
- Anti‐epidermal growth factor receptor therapy for glioblastoma in adults